Market Place
Sourcing Support
Roche’s Alecensa receives NICE to treat ALK-positive lung cancer
22 Oct 2024 //
PMLIVE
Chugai`s Alecensa Approved In Japan For Early-Stage ALK+ NSCLC
29 Aug 2024 //
PHARMABIZ
Taiwan FDA Approves Chugai`s Alecensa For Early Stage ALK+ NSCLC
03 Aug 2024 //
PHARMABIZ
EU Approves Roche`s Alecensa As Targeted Adjuvant For ALK+ Lung Cancer
10 Jun 2024 //
GLOBENEWSWIRE
FDA Approves Roche`s Alecensa As First ALK+ Early Lung Cancer Drug
19 Apr 2024 //
GLOBENEWSWIRE
Alecensa approved as 1st adjuvant for ALK+ early lung cancer
18 Apr 2024 //
BUSINESSWIRE
ESMO: Roche`s Alecensa cuts postsurgery lung cancer recurrence
21 Oct 2023 //
FIERCE PHARMA
Genentech’s Alecensa Reduces the Risk of Death by an Unprecedented 76%
18 Oct 2023 //
BUSINESSWIRE
Roche claims study success for targeted drug in early lung cancer
02 Sep 2023 //
BIOPHARMADIVE
Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC
01 Sep 2023 //
ONCLIVE
Roche`s Alecensa stays on top of Xalkori at 5-year mark
13 May 2020 //
FIERCE PHARMA
NICE final guidance backs Pfizer`s Lorviqua
13 May 2020 //
PHARMA TIMES
New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment
07 May 2020 //
GLOBENEWSWIRE
Roche to present new data from its broad oncology portfolio at the EU Society
23 Sep 2019 //
ROCHE
Shrinking 60% of lung cancers, Blueprint`s RET drug poised for 2020 filing
04 Jun 2019 //
FIERCE BIOTECH
Soliris (eculizumab) : Chugai Pharmaceutical vs. Alexion Pharmaceuticals
26 Nov 2018 //
PATENT LITIGATION
U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC
02 Nov 2018 //
BUSINESSWIRE
Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?
02 Nov 2018 //
ENDPTS
Takeda`s Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
26 Sep 2018 //
FIERCE PHARMA
Chugai Pharma receives Taiwan FDA approval for Alecensa to treat ALK
16 May 2018 //
PHARMABIZ
Roche Korea’s Alecensa gets approval as 1st line lung cancer therapy
13 Apr 2018 //
KOREABIOMED
NICE no for Roche’s Alecensa
11 Apr 2018 //
PHARMA TIMES
Pfizer files third-gen ALK inhibitor for lung cancer
14 Feb 2018 //
PMLIVE
Roche scores cancer drug approvals in Europe and US
21 Dec 2017 //
PREE RELEASE
EU OKs first-line use of Roche’s lung cancer drug Alecensa
21 Dec 2017 //
PHARMA TIMES
Roche’s Alecensa wins wider US approval for lung cancer
08 Nov 2017 //
PHARMA TIMES
CHMP recommends EU approval of Roche’s Alecensa as a first-line treatment
13 Oct 2017 //
PRESS RELEASE
Roche`s Alecensa bests Pfizer`s Xalkori in lung cancer trial
05 Jun 2017 //
REUTERS
Roche’s Alecensa beats Pfizer’s Xalkori in lung cancer trial
10 Apr 2017 //
PHARMA TIMES
Chugai receives Taiwan nod for Alecensa
27 Feb 2017 //
BIOSPECTRUM
Novartis` Zykadia scores priority review and breakthrough designation from FDA
24 Feb 2017 //
PHARMAFILE
EU nod for Roche’s lung cancer drug Alecensa
22 Feb 2017 //
PHARMATIMES
Roche’s lung cancer drug Alecensa wins EU approval
22 Feb 2017 //
PMLIVE
Chugai’s Alecensa receives European conditional marketing authorization
21 Feb 2017 //
PHARMABIZ
Tecentriq growth offsets Avastin`s US decline at Roche
02 Feb 2017 //
PMLIVE
Competition Stalls Roche Margin Growth; Drugmaker Commits to Diabetes Unit
02 Feb 2017 //
REUTER
December CHMP decisions bring year’s total approvals to 81
03 Jan 2017 //
PHARMATIMES
Roche say cancer drug Alecensa gets breakthrough therapy designation
05 Oct 2016 //
REUTERS
